Results 171 to 180 of about 101,002 (279)

If treating obesity with GLP‐1‐based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials

Diabetes, Obesity and Metabolism, EarlyView.
Anastasios Tentolouris, Ioannis Ntanasis‐Stathopoulos   +1 more
wiley   +1 more source

Efficacy of Weight‐Lowering Agents on Fat Distribution: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Obesity Reviews, EarlyView.
ABSTRACT Background Pharmacotherapy offers a potential solution for individuals with overweight and obesity to decrease their body weight. However, there is limited knowledge of the effects of antiobesity agents on the distribution of body fat. Methods The PubMed, Embase, and Cochrane Library databases were reviewed for randomized controlled trials ...
Xiuqi Qiao, Weihao Wang, Jiaming Cao, Lixin Guo, Qi Pan   +4 more
wiley   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

Medicinal Research Reviews, Volume 46, Issue 2, Page 475-512, March 2026.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek   +3 more
wiley   +1 more source

Increased Hepatic Myeloperoxidase Activity in Obese Subjects with Nonalcoholic Steatohepatitis [PDF]

, 2009
Sander S. Rensen, Yanti Slaats, Jeroen Nijhuis, Anneke Jans, Veerle Bieghs, Ann Driessen, Ernst Malle, Jan Greve, Wim A. Buurman   +8 more
openalex   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?

, 2015
Paola Dongiovanni, Raffaela Rametta, Marica Meroni, Luca Valenti   +3 more
openalex   +2 more sources

Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis

, 2020
Sudhir Kumar, Alok Kumar Verma, Richa Rani, Akanksha Sharma, Jiang Wang, Shimul A. Shah, Jaideep Behari, Rosa Salazar Gonzalez, Rohit Kohli, Chandrashekhar R. Gandhi   +9 more
openalex   +2 more sources

Nonalcoholic Fatty Liver Disease Status and Its Associated Factors Among Patients With Type 2 Diabetes Mellitus in Adama Hospital Medical College, South Eastern Ethiopia: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background and Aims Nonalcoholic fatty liver disease (NAFLD) is a condition of fat accumulation in hepatocytes, not because of excess alcohol intake and disease‐causing etiology. The disease occurrence is increased among patients with type 2 diabetes mellitus (T2DM) because of a strong pathophysiological link.
Mahider Shimelis Feyisa, Sintayehu Ambachew, Alemie Fentie Mebratie, Bruktawit Eshetu Ali, Rishan Hadgu Asefa, Elias Chane Asefa, Mahder Girma Asmamaw, Getnet Fetene   +7 more
wiley   +1 more source

MiR‐18a‐5p Attenuates Oxidative Stress and Inhibits Lipid Accumulation in Alcoholic Fatty Liver by Activating the CYP1A1‐PPAR Axis

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
ABSTRACT Background Lipid deposition in alcoholic fatty liver disease (AFL) represents an early stage in alcoholic liver disease progression and may contribute to carcinogenesis. MicroRNAs (miRNAs) play critical regulatory roles in liver biological processes. Methods In this study, we explored the miR‐18a‐5p/CYP1A1/PPAR axis in AFL using bioinformatics
XueMei Zhang, Wei Li, Ubaid Ullah, Ning Li, XinYu Geng, JiHan Qi, HongLiang Chen, Xu Zhang, Ying Hu, Lingling Yang, ShiZhu Jin   +10 more
wiley   +1 more source

Additional file 5: of Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA/circRNA immune ceRNA networks

, 2019
Mingzhe Zhu, Meng Li, Wenjun Zhou, Yang Yang, Fenghua Li, Li Zhang, Guang Ji   +6 more
openalex   +1 more source